CTKB
Cytek Biosciences Inc
5.90$
+1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -4.8% | -0.5% | -1.7% | +1.6% | +1.7% | -3.4% | +2.2% | +0.3% | -6.7% | -2.7% | -0.5% | |
| – | -7.2% | -0.9% | -1.2% | +1.6% | +1.6% | -4.0% | +0.6% | +1.5% | +0.9% | -3.2% | -0.4% | |
| – | +2.2% | +0.9% | +5.4% | -8.8% | -39.2% | -3.5% | -20.8% | +23.6% | -2.6% | -27.7% | +12.5% | |
| – | -8.9% | +2.9% | +2.6% | +0.2% | +0.0% | -4.4% | -1.4% | -0.1% | -0.1% | +0.3% | -0.1% | |
| – | -2.6% | -10.2% | -11.2% | +17.7% | +15.1% | -8.9% | +2.6% | +8.8% | +17.0% | -21.7% | -9.2% | |
| – | -9.0% | -10.1% | -8.5% | -6.5% | -6.2% | +3.3% | +9.1% | +4.4% | -6.2% | +2.8% | +4.9% | |
| – | -1.7% | +0.0% | +0.0% | +0.0% | +3.0% | +0.1% | +0.2% | -0.1% | 0.0% | 0.0% | +0.0% | |
| – | -5.0% | -3.6% | -3.7% | -4.3% | -1.8% | -3.5% | -4.3% | -5.0% | -4.8% | -6.6% | -5.3% | |
| – | -2.4% | -1.9% | -4.9% | +11.8% | -1.9% | -0.8% | +12.4% | +0.5% | +3.0% | +1.4% | +2.9% | |
| – | -4.2% | -1.2% | -5.7% | +19.9% | +7.7% | +0.0% | +8.2% | +2.6% | +3.5% | +4.0% | +4.2% | |
| – | -12.2% | +40.2% | +2.7% | +27.5% | +52.3% | -10.5% | +16.4% | +46.6% | -28.6% | +72.9% | -20.0% | |
| – | -35.6% | +22.9% | -14.3% | +68.9% | +2.6% | +13.0% | +9.7% | +11.4% | -16.0% | +5.2% | +24.7% | |
| – | -5.1% | -10.4% | -10.0% | -7.1% | -15.0% | -12.6% | -13.8% | -17.2% | -19.8% | -26.5% | -36.3% | |
| – | -5.4% | -0.1% | -0.9% | -0.9% | +2.7% | -4.1% | -0.5% | +0.3% | -9.7% | -4.1% | -1.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.0% | +0.2% | +0.4% | +1.0% | -2.7% | -0.7% | -1.1% | +0.5% | +0.5% | +0.4% | +0.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.